Qure.ai vs Viz.ai
Hemorrhage triage on head CT is where Qure and Viz.ai overlap. Qure's qER holds a 510(k) for CT triage, and Viz ICH holds its own, first decided in March 2020. Viz.ai builds the pathway around the alert: a mobile app and group messaging that coordinate transfer, a De Novo authorization for ContaCT large vessel occlusion triage on CTA, and modules for aneurysm, PE, aortic disease and HCM. A meta-analysis of 12 studies and 15,595 patients on Viz.ai use found shorter door-to-groin and door-in-door-out times and no significant difference in clinical outcomes.
For a regional stroke network that coordinates transfers between spoke hospitals, Qure falls behind. A hospital with no transfer partner gains little from that coordination layer, and Qure is the nearer fit. Its qXR-PTX-PE triages pneumothorax and effusion on chest X-ray, and qCT LN Quant measures and tracks nodule volumes on CT.
Radiology · Reviewed November 2, 2026
When to pick each one
Qure.ai
- qXR-PTX-PE triage for pneumothorax and effusion
- qCT LN Quant for nodule volumetry and tracking
- qER head CT triage, 510(k) cleared
Viz.ai
- Mobile alerts and group messaging coordinate transfers
- ContaCT De Novo plus 510(k)s for ICH, SDH and aneurysm
- Cardiac modules for HCM, ACS and amyloidosis
Score
Each row shows points earned of points available under the published rubric.
Qure.ai
50of 100
Viz.ai
89of 100
| Dimension | Qure.ai | Viz.ai | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 10 / 10 | -10 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 12.7 / 18.2 | 18.2 / 18.2 | -5.5 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 7.8 / 7.8 | -7.8 |
| Funding & adoption signal | 8.4 / 12 | 12 / 12 | -3.6 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 0 / 6 | 6 / 6 | -6 |
Scroll horizontally to see every column.
Pricing
Qure.ai
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Grant funding is not stated on Qure pages. |
Viz.ai
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Sold to health systems after a demo request. |
Evidence
Qure.ai
FDA decisions
K261517 (opens in new tab)510(k)2026-09-14
qCT Lung v1.0
K251934 (opens in new tab)510(k)2026-01-16
qXR-Detect
K251610 (opens in new tab)510(k)2025-09-08
qER-CTA v1.0
K240740 (opens in new tab)510(k)2024-08-16
qCT LN Quant
K231805 (opens in new tab)510(k)2023-12-22
qXR-LN
Show 5 more
K231149 (opens in new tab)510(k)2023-09-22
qXR-CTR
K230899 (opens in new tab)510(k)2023-08-22
qXR-PTX-PE
K212690 (opens in new tab)510(k)2021-12-21
qXR-BT
K211222 (opens in new tab)510(k)2021-07-30
qER-Quant
K200921 (opens in new tab)510(k)2020-06-17
qER
Peer-reviewed
4 PubMed records name Qure.ai.
- Radiograph accelerated detection and identification of cancer in the lung (RADICAL): a mixed methods study to assess the clinical effectiveness and acceptability of Qure.ai artificial intelligence software to prioritise chest X-ray (CXR) interpretation. (opens in new tab)
- Revolutionizing Healthcare: Qure.AI's Innovations in Medical Diagnosis and Treatment. (opens in new tab)
- A Case Series From a Multicentric Study: Can Artificial Intelligence (AI)-Enabled Chest X-Ray Assist in the Incidental Detection of Early-Stage Lung Cancers? (opens in new tab)
Viz.ai
FDA decisions
K250354 (opens in new tab)510(k)2025-06-10
Viz Subdural+
K232363 (opens in new tab)510(k)2024-02-05
Viz HDS, Viz Volume Plus, Viz ICH+
DEN230003 (opens in new tab)De Novo2023-08-03
Viz HCM
K223443 (opens in new tab)510(k)2023-03-17
Viz AAA
K223042 (opens in new tab)510(k)2022-10-21
Viz LVO (ContaCT)
Show 7 more
K221100 (opens in new tab)510(k)2022-08-29
Viz RV/LV
K220439 (opens in new tab)510(k)2022-07-25
Viz SDH
K213319 (opens in new tab)510(k)2022-02-18
Viz ANEURYSM
K210209 (opens in new tab)510(k)2021-03-23
Viz ICH
K193658 (opens in new tab)510(k)2020-03-18
Viz ICH
K180161 (opens in new tab)510(k)2018-04-20
Viz CTP
DEN170073 (opens in new tab)De Novo2018-02-13
ContaCT
Peer-reviewed
5 PubMed records name Viz.ai.
- Automated Emergent Large Vessel Occlusion Detection Using Viz.ai Software and Its Impact on Stroke Workflow Metrics and Patient Outcomes in Stroke Centers: A Systematic Review and Meta-analysis. (opens in new tab)
- Revolutionizing Intracranial Hemorrhage Diagnosis: A Retrospective Analytical Study of Viz.ai ICH for Enhanced Diagnostic Accuracy. (opens in new tab)
- Real-world evaluation of the accuracy of the Viz.AI automated intracranial hemorrhage volume calculation tool. (opens in new tab)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | Qure.ai | Viz.ai |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | n/a | 2016 |
| HQ | IN | US |
Scroll horizontally to see both columns.
Common questions
Open the full radiology comparison
Acute-care triage, mammography screening, CCTA plaque analysis, mobile MRI. 30+ FDA-cleared platforms across stroke, oncology, cardiac. Enterprise sales only — we compared what's deployed where.


